Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search

New Indication: Enasidenib in older patients with late-stage mutant-IDH2 relapsed/refractory AML

New Indication: Enasidenib in older patients with late-stage mutant-IDH2 relapsed/refractory AML
Study:
  • Phase III, randomized, open-label study
  • Patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies
  • Enasidenib (n=158) vs. CCR (azacitidine, intermediate-dose cytarabine, low-dose cytarabine, or supportive care) (n=161)
Efficacy:
  • mOS: 6.5 vs. 6.2 mos, HR:0.86, p=0.230
  • mEFS: 4.9 vs. 2.6 mos , HR:0.68, p=0.008
  • ORR: 40.5% vs. 9.9%
Safety:
  • Any grade AEs: nausea (22% vs. 16%), Bilirubin increased (19.7% vs. 0.7%), thrombocytopenia (15.3 % vs. 10.6%), neutropenia (8.3% vs. 12.1%)
  • Grade 5 AEs: 1 pts in the enasidenib arm (hepatic failure during cycle 2) and 5 pts in the CCR arm (acute myocardial infarction [during follow-up], cerebral hemorrhage [on day 14], febrile neutropenia [on day 37], pneumonia [on day 13], and sepsis [on day 5]).

Blood (2023) 141 (2): 156–167.

Botton S et al. ¨Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial¨

http://doi.org/blood.2021014901

Reviewed by Elvin CHALABİYEV, MD on FEB 24, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More